Funds tied to Aurinia Pharmaceuticals (AUPH) add shares, sell put options
Rhea-AI Filing Summary
Aurinia Pharmaceuticals Inc. insider entities associated with Chief Executive Officer Kevin Tang reported significant open-market buying of common shares and new derivative positions. Funds managed through Tang Capital partnerships bought a net 814,606 common shares in late May and early June at prices around $15 per share, bringing their indirect holdings to 13,044,106 shares.
In a separate move, Tang-affiliated funds sold 10,000 short put options, creating a potential obligation to acquire up to 1,000,000 additional common shares at $15 per share if exercised by January 15, 2027. Together, these transactions increase the funds’ equity exposure to Aurinia while adding conditional future buying commitments.
Positive
- None.
Negative
- None.
Insights
CEO-linked funds increased Aurinia exposure via share purchases and short puts.
Funds associated with Kevin Tang acquired 814,606 Aurinia common shares through open-market purchases around $15 per share, raising their indirect position to 13,044,106 shares. These are discretionary buys, not option exercises or tax-driven moves.
The same funds entered into 10,000 short put options with a $15 strike, expiring on January 15, 2027. This structure adds downside obligation to buy up to 1,000,000 shares if assigned. Actual impact on share count and liquidity will depend on future market prices and whether counterparties exercise.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Short Put Options (potential obligation to buy) | 10,000 | $1.65 | $17K |
| Purchase | Common Shares | 206,005 | $15.28 | $3.15M |
| Purchase | Common Shares | 343,521 | $15.28 | $5.25M |
| Purchase | Common Shares | 99 | $15.34 | $2K |
| Purchase | Common Shares | 2,299 | $15.35 | $35K |
| Purchase | Common Shares | 262,682 | $15.31 | $4.02M |
Footnotes (1)
- The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $15.33 to $15.38. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 through 6. Tang Capital Partners, LP ("TCP") beneficially owns 7,205,442 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 5,239,039 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 324,814 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 274,811 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV (collectively, the "Funds"). These shares were purchased in multiple transactions ranging from $15.05 to $15.37. These shares were purchased in multiple transactions ranging from $14.97 to $15.50. These shares were purchased at $15.34. These shares were purchased in multiple transactions ranging from $15.00 to $15.40. Each put option is exercisable only at the option of the counterparty through the expiration date of the put option. Securities are beneficially held by TCP III and TCP IV. The Funds sold 10,000 put options on June 2, 2026. Pursuant to the put option contracts, the Funds have the potential obligation to acquire 1,000,000 common shares of the Issuer at $15 expiring on January 15, 2027.